SCHEMBL1708883

SCHEMBL1708883

COc1c(N)cccc1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.55
ALDH1A1 P00352 5/20 0.48
HSD17B10 Q99714 4/20 0.48
CFTR P13569 1/20 0.48
KDM4E B2RXH2 3/20 0.47
MAPK1 P28482 1/20 0.47
HPGD P15428 1/20 0.47
CASR P41180 1/20 0.46
G6PD P11413 1/20 0.46
CASP7 P55210 1/20 0.46
CASP6 P55212 1/20 0.46
APEX1 P27695 4/20 0.44
MAPT P10636 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HTT P42858 1/20 0.44
NPC1 O15118 1/20 0.44
CASP3 P42574 1/20 0.44
RAB9A P51151 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31226473 1.00 MMP2 (0.55) MMP2ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL27995741 0.98 MMP2 (0.53) MMP2ALDH1A1HSD17B10CFTRKDM4E
Hydrochloric Acid SCHEMBL29744423 0.98 MMP2 (0.53) MMP2ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL39857 0.86 ALDH1A1 (0.55) ALDH1A1HSD17B10KDM4EMAPK1HPGD
SCHEMBL8718150 0.85 ALDH1A1 (0.72) MMP2ALDH1A1HSD17B10KDM4EHPGD
Mesalamine SCHEMBL8720354 0.85 ALDH1A1 (0.61) MMP2ALDH1A1HSD17B10KDM4EHPGD
SCHEMBL9818242 0.85 ALDH1A1 (0.48) MMP2ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL7106629 0.85 ALDH1A1 (0.48) MMP2ALDH1A1HSD17B10CFTRKDM4E
SCHEMBL29430315 0.85 ALDH1A1 (0.48) MMP2ALDH1A1HSD17B10CFTRKDM4E
Hydrochloric Acid SCHEMBL699717 0.84 ALDH1A1 (0.53) ALDH1A1HSD17B10KDM4EMAPK1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110997810-A Electrically conductive biomaterials comprising benzoic acid based polymers for enhancing tissue conductivity in vitro and in vivo 大学健康网络 2020-04-10 CN claimed
US-10385096-B2 Pro-Amb reverse turn restricted bioactive peptide analogues COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-08-20 US claimed
US-20180273819-A1 THERMAL ENERGY STORAGE PHASE AND TEMPERATURE STABILIZATION CHANGE MATERIALS COMPRISING TRIAMINES AND METHODS FOR MAKING AND USING THEM ENTROPY SOLUTIONS LLC (US) 2018-09-27 US claimed
US-20180057529-A1 PRO-AMB REVERSE TURN RESTRICTED BIOACTIVE PEPTIDE ANALOGUES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-03-01 US claimed
WO-2016179028-A1 THERMAL ENERGY STORAGE PHASE AND TEMPERATURE STABILIZATION CHANGE MATERIALS AND METHODS FOR MAKING AND USING THEM ENTROPY SOLUTIONS, LLC. (US) 2016-11-10 WO claimed
WO-2003016615-A1 SINGLE BATH PROCESS FOR BLEACHING AND DYEING TEXTILES NOVOZYMES NORTH AMERICA, INC. (US) 2003-02-27 WO claimed
EP-4709712-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF Blueprint Medicines Corporation (US) 2026-03-18 EP disclosed
CN-114057651-B Amide group-containing TYK2 inhibitor compounds 正大天晴药业集团股份有限公司 2025-05-27 CN disclosed
EP-3848370-B1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICALS CO (JP) 2025-05-07 EP disclosed
CN-114907326-B TYK2 inhibitor compounds containing an amide group and a bicyclic ring 正大天晴药业集团股份有限公司 2025-02-18 CN disclosed
US-20240425456-A1 DEGRADER ASKA PHARMACEUTICAL CO., LTD. (JP) 2024-12-26 US disclosed
WO-2024233900-A1 GSK3A INHIBITORS AND METHODS OF USE THEREOF BLUEPRINT MEDICINES CORPORATION (US) 2024-11-14 WO disclosed
EP-4410806-A1 DEGRADATION INDUCER ASKA Pharmaceutical Co., Ltd. (JP) 2024-08-07 EP disclosed
US-5498618-A ANTAGONISM OF 5-HT2 JANSSEN PHARMACEUTICA N.V. (BE) 1996-03-12 US disclosed
EP-0650475-A1 4-AMINO-N --(4-METHYL-4-PIPERIDINYL)-2-METHOXYBENZAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1995-05-03 EP disclosed
WO-1994002462-A1 4-AMINO-N^_-(4-METHYL-4-PIPERIDINYL)-2-METHOXYBENZAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1994-02-03 WO disclosed
EP-0190915-B1 Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides SYNTHELABO (FR) 1992-10-28 EP disclosed
US-4870181-A AMIDATION OF 3-AMINOQUINUCLIDINE SALT A. H. ROBINS COMPANY, INCORPORATED (US) 1989-09-26 US disclosed
EP-0190915-A2 Process for the preparation of 2-alkoxy-N-(1-azabicyclo[2.2.2]octan-3-yl) aminobenzamides SYNTHELABO (FR) 1986-08-13 EP disclosed
US-4036951-A SUNSCREEN AGENTS SYNERGISTICS, INC. (US) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425456-A1 DEGRADER JAK3, JAK1, JAK2 MMP2 1847/4885ALDH1A1 4053/4885HSD17B10 2068/4885
US-20180057529-A1 PRO-AMB REVERSE TURN RESTRICTED BIOACTIVE PEPTIDE ANALOGUES APP, FURIN, PREP MMP2 960/4885ALDH1A1 4716/4885HSD17B10 2463/4885
US-10385096-B2 Pro-Amb reverse turn restricted bioactive peptide analogues APP, FURIN, PREP MMP2 1003/4885ALDH1A1 4702/4885HSD17B10 2485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.